Avid Bioservices Inc (CDMO)

[biopharm]

Would one of you medically inclined posters help me with that?

Tech-clone, "upstream" can be related back to Notch Signaling in general.

There are 4 ways cells communicate with one another, and these will play into how the new blood test will be developed.

1) Autocrine
2) Endocrine
3) Paracrine
4) Intracrine

http://openi.nlm.nih.gov/imgs/512/335/3382770/3382770_ijms-13-06053f1.png

---------------------------------------------------------

Now, generally... in the past, especially with chemos--- they have always used their drugs to target "intrusively to the cell" = which is considered downstream -- vs --- Bavituximab (targeting flipped-PS) actually has been targeting that sits on the outer edge of the cell membrane. What do we think happens to those chemo drugs that enter a cell to work? What kind of Notch Signaling pathway type interference is happening and disturbed? These side affects are turning some of those ways cells communicate all upside down, ultimately causing side affects because there immune system is suppressed.

Now, it just so happens that flipped-PS allows for an optimal immune response by hitting just the right target = flipped-PS = which is the most upstream target that anyone has targeted to date. Peregrine still has to update us more on this new understanding of the MOA, but I'm sure they do not want to give away too much info, patent related...and Notch Signaling related, because once that is known-- thich they must. Then, you can develop a blood test that looks, exactly for those conditions and can determine if you are on the path back to a "quality of life" which is the #1 goal for all. The FDA would look mighty good with such approval of a new blood test, since it will avoid thousands of patients sitting in trials on drugs, they know will not provide an optimal immune response (without a PS Targeting type drug)

http://www.nature.com/ncb/journal/v13/n12/images/ncb2382-f1.jpg